Lowest recommended Gd dose
among general-use GBCAs
VUEWAY® provides effective contrast enhancement at half the gadolinium dose
(0.05 mmol/kg) vs. a macrocyclic GBCA at a dose of 0.1 mmol/kg in approved indications.1
References
1 VUEWAY® (gadopiclenol) SmPC, EMA, 10/2022.
2 Robic C, Port M, Rousseaux O, et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate with High T1 Relaxivity. Invest Radiol. 2019; 54: 475-484.
3 GADOVIST® (gadobutrol) SmPC, 07/2022.
4 ProHance® (gadoteridol) SmPC UK, 11/2022.
5 DOTAREM® (gadoterate meglumine) SmPC 07/2022.
6 CLARISCAN™ (gadoterate meglumine) SmPC UK, 05/2023.